Value in, value out

With a greater focus on accelerating development timelines, investors are expecting quicker returns. How can we accelerate products to deliver maximum value for patients and investors?


KATH MACKAY | Director of Life Sciences | Bruntwood SciTech – Alderley Park


ANDY HILL | Chief Executive Officer | Nu-Vision Biotherapies
KOUJIRO TAMBARA | Principal | Downing
LOUWAI MUHAMMED | CEO and Co-Founder | CoSyne Therapeutics
CLARE TRIPPETT | Chief Technologist – Biologics | CPI
MARTIN DOORBAR | Chief Development Officer; Non Clinical |  Ellipses
JAMIE UNWIN | Commercial Insight Officer | Nanoform